Annals of the rheumatic diseases
Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease.
Baptiste Chevet, Valérie Devauchelle-Pensec, Elena Pontarini, Valentin Baloche, Michele Bombardieri, Simon J Bowman, Michael Barnes, Antoine G Sreih, Jinqi Liu, Sheila Kelly, Antonia Christodoulou, Philippe Moingeon, Laurence Laigle, Perrine Soret, Christelle Le Dantec
Published: 202510.1016/j.ard.2025.11.017
Abstract
OBJECTIVES: Sjögren's disease (SjD) is clinically and biologically heterogeneous, and no immunomodulatory drug has yet demonstrated efficacy in phase 3 trials. We previously identified 4 transcriptomic endotypes in SjD patients using whole-blood RNA…
Preview only. Read the full abstract at the source